Raltitrexed

Third-line Treatment

China Medical University, ChinaSmall moleculePhase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 95/ 100

Competitive context

180 Active assets in the Third-line Treatment cohort.

Asset / Sponsor	Phase	Rating
Catequentinib Nanfang Hospital, Southern Medical University	Phase 3	BB
Irinotecan M.D. Anderson Cancer Center	Phase 2	BB
Durvalumab OHSU Knight Cancer Institute	Phase 2	BB
Cediranib National Cancer Institute (NCI)	Phase 2	BB
Nivolumab CatalYm GmbH	Phase 2	BB

View all 50 →

Same molecule, other indications

Raltitrexed is also rated in:

Hepatic Arterial Infusion ChemotherapyDormant

BBB

Indicative ·

74 / 100

Colon Cancer Liver MetastasisDormant

BB

Indicative ·

71 / 100

Hepatocellular CarcinomaDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.